Baseline use of proton pump inhibitors and antibiotics significantly reduces progression-free and overall survival in unresectable stage III NSCLC patients treated with durvalumab, with hazard ratios up to 1.66.
- Open access
- 7 cites
Immunotherapy and Immune Responses
Moving in The Lancet Oncology.
- Moved this week
- 1
Rebuilt
Moved this week
Latest in Immunotherapy and Immune Responses
Newest first · last 60 days
TLR9 agonists enhance adoptive T cell therapy by activating a B cell-CD2 costimulatory pathway, leading to improved tumor control and T cell function.
- Open access
Monocyte-derived galectin-1(hi) cells are essential for generating and maintaining lung tissue-resident memory CD8+ T cells after influenza infection, with over 4 months persistence.
- 1 cites
Immune checkpoint inhibitor combinations have become the standard first-line systemic therapy for HCC, significantly improving survival and response rates over previous treatments.
- Open access
CAR-T cell therapies and cancer nanovaccines show promise but face distinct translational challenges, with recent advances highlighting their potential to reshape cancer treatment.
- Open access
Synthetic pH-responsive membranolytic peptide induces immunogenic cell death, boosting immune checkpoint therapy efficacy in tumors with 50% enhanced response.
Intestinal epithelial cells presenting cytosol-delivered bacterial antigens program robust barrier immune memory, with significantly enhanced responses compared to bacterial retention.
- Open access
- 1 cites
Metastasis promotes tumor immunogenicity by producing migrasomes that deliver antigens and activate immune responses, reducing metastatic growth.
- Open access
CD40 activation in B cells enhances anti-tumor immunity by promoting CD8+ T cell infiltration and cytotoxic function in high-mutation tumors.
- Open access
A super enhancer between HLA-DR and -DQ genes regulates their expression through microdomains, with specific regions controlling HLA-DQA1 and HLA-DRB1 levels.
- Open access
Cancers evade T cell detection by restricting presentation of p53 neoantigens, with 70% of hotspot mutations avoiding display in tumors.
PreGame identifies tumour-reactive γδ T-cell receptors with broad reactivity, revealing potential for universal immunotherapy in multiple myeloma and other cancers.
- Open access
Combining cyclophosphamide with immune checkpoint blockade expands effector CD8+ T cell clones, delaying tumor progression in multiple cancer models.
AI-driven integration of multi-modal single-cell genomics and reverse vaccinology enables de novo design of personalized multi-epitope cancer vaccines, advancing immunotherapy.
- Open access
Elevated NF-κB activity in CD4 CAR-T cells predicts durable responses and improved survival in multiple myeloma patients treated with ide-cel.
Arlocabtagene autoleucel achieves an 87% overall response rate with durable responses in heavily pretreated relapsed/refractory multiple myeloma patients.
- Open access
- 5 cites
Allogeneic BCMA CAR T cells armed with NKG2A receptor (CT0590) effectively resist host NK cell attacks and show durable responses in multiple myeloma patients.
Combining radiotherapy and immunotherapy offers a promising approach to improve survival in localized pancreatic ductal adenocarcinoma, despite current challenges.
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res483
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ199
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- J Exp Bot115
- Curr Biol112
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4